These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16982301)

  • 1. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study.
    Nguyen NT; Cook DM; Bero LA
    Clin Ther; 2006 Aug; 28(8):1231-1243. PubMed ID: 16982301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021.
    Daval CJR; Teng TW; Russo M; Kesselheim AS
    JAMA Health Forum; 2023 Jul; 4(7):e231718. PubMed ID: 37418270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.
    Zhang AD; Schwartz JL; Ross JS
    Milbank Q; 2019 Sep; 97(3):796-819. PubMed ID: 31304643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching omeprazole in Sweden and the United States.
    Cohen J
    Am J Ther; 2003; 10(5):370-6. PubMed ID: 12975722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.
    Lurie P; Almeida CM; Stine N; Stine AR; Wolfe SM
    JAMA; 2006 Apr; 295(16):1921-8. PubMed ID: 16639051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAA.
    Morrato EH; Ling SB
    Med Care; 2012 Nov; 50(11):970-86. PubMed ID: 23047787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advisory committees; OTC Drugs Advisory Committee; establishment--FDA. Final rule.
    Fed Regist; 1991 Sep; 56(185):48103-4. PubMed ID: 10114368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. United States Food and Drug Administration Advisory Committee outcomes and agency approval analysis from 2010 to 2015.
    McCormack Z
    J Am Pharm Assoc (2003); 2018; 58(5):530-533. PubMed ID: 30005816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does seating location impact voting behavior on Food and Drug Administration advisory committees?
    Broniatowski DA; Magee CL
    Am J Ther; 2013; 20(5):502-6. PubMed ID: 21642834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FDA Acetaminophen Advisory Committee Meeting - what is the future of acetaminophen in the United States? The perspective of a committee member.
    Krenzelok EP
    Clin Toxicol (Phila); 2009 Sep; 47(8):784-9. PubMed ID: 19735211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.
    Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED;
    Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.
    Cook DM; Gurugubelli RK; Bero LA
    Drug Saf; 2009; 32(11):1057-66. PubMed ID: 19810777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs.
    Daval CJR; Sarpatwari A; Kesselheim AS
    Health Aff (Millwood); 2022 May; 41(5):713-721. PubMed ID: 35500185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting financial conflicts of interest in FDA advisory committees.
    Pham-Kanter G
    Milbank Q; 2014 Sep; 92(3):446-70. PubMed ID: 25199895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disagreements Between FDA and its Oncologic Drugs Advisory Committee (ODAC).
    Ayon Verduzco A; Yeboah K
    Ther Innov Regul Sci; 2021 Jan; 55(1):98-110. PubMed ID: 32767033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
    Shih YC; Prasad M; Luce BR
    Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings.
    Hayes MJ; Prasad V
    Hastings Cent Rep; 2018 Mar; 48(2):10-13. PubMed ID: 29590518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The First 10 Years: Reflecting on Opportunities and Challenges of the Tobacco Products Scientific Advisory Committee of the United States Food and Drug Administration.
    Fagan P; Eissenberg T; Jones DM; Cohen JE; Nez Henderson P; Clanton MS
    J Leg Med; 2020; 40(3-4):293-320. PubMed ID: 33797324
    [No Abstract]   [Full Text] [Related]  

  • 20. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids.
    Miller CJ; Dart RC; Katz NP; Webster LR
    J Opioid Manag; 2017; 13(6):379-389. PubMed ID: 29308585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.